Viridian Therapeutics, Inc.
General ticker "VRDN" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $2.1B (TTM average)
Viridian Therapeutics, Inc. follows the US Stock Market performance with the rate: 1.9%.
Estimated limits based on current volatility of 2.6%: low 17.97$, high 18.86$
Factors to consider:
- Total employees count: 252 (+76.2%) as of 2025
- Top business risk factors: R&D failure, Regulatory and compliance, Manufacturing risks, Market acceptance, Labor/talent shortage/retention
- Price in estimated range
- Earnings for 3 months up through Q1 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [16.61$, 46.90$]
- 2026-12-31 to 2027-12-31 estimated range: [9.82$, 30.23$]
Financial Metrics affecting the VRDN estimates:
- Negative: with PPE of -9.7 at the end of fiscal year the price was high
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Negative: negative Net income
- Positive: -4.39 < Investing cash flow per share per price, % of -1.39
- Positive: Shareholder equity ratio, % of 80.29 > 64.23
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term VRDN quotes
Long-term VRDN plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.31MM | $0.30MM | $70.85MM |
| Operating Expenses | $254.76MM | $299.34MM | $434.24MM |
| Operating Income | $-254.45MM | $-299.04MM | $-363.39MM |
| Non-Operating Income | $16.72MM | $29.09MM | $20.79MM |
| Interest Expense | $1.33MM | $2.20MM | $4.95MM |
| R&D Expense | $159.76MM | $238.25MM | $338.93MM |
| Income(Loss) | $-237.73MM | $-269.95MM | $-342.60MM |
| Net Income(Loss)* | $-237.73MM | $-269.95MM | $-342.60MM |
| Stockholders Equity | $442.02MM | $671.64MM | $722.17MM |
| Assets | $490.42MM | $742.40MM | $899.42MM |
| Operating Cash Flow | $-184.17MM | $-232.32MM | $-276.39MM |
| Capital expenditure | $0.90MM | $0.51MM | $0.49MM |
| Investing Cash Flow | $-94.25MM | $-228.65MM | $-37.56MM |
| Financing Cash Flow | $225.67MM | $457.74MM | $426.74MM |
| Earnings Per Share** | $-5.31 | $-3.98 | $-4.04 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.